Story

Bristol Myers Squibb to Build $2.3 Billion Manufacturing Plant in Houston

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20261 min read
Bristol Myers Squibb to Build $2.3 Billion Manufacturing Plant in Houston
Text size
Background

Bristol Myers Squibb on Monday announced plans to invest approximately $2.3 billion to construct a new manufacturing facility in Houston, Texas. The project is part of a previously declared $40 billion commitment to U.S. investments by the pharmaceutical giant and is expected to significantly expand its domestic production capacity.

Investment and Job Creation

The New Jersey-based company stated that the new site will create nearly 500 skilled, full-time jobs. The construction phase, slated to run from 2027 to 2030, is projected to generate an additional 2,000 temporary jobs in construction and related fields.

In a statement, Texas Governor Greg Abbott confirmed the state's support for the project, which includes a $4.89 million grant from the Texas Enterprise Fund. The facility also qualifies for benefits under the state’s Jobs, Energy, Technology and Innovation (JETI) program.

Facility Capabilities

Sample IUX Markets – In-articleAd

The planned campus will span roughly 600,000 square feet and is being designed for advanced manufacturing. According to Bristol Myers, the site will be equipped to produce a range of medicines, including small-molecule therapies as well as more complex treatments like biologics and antibody-drug conjugates.

The company emphasized that the facility will be built with flexibility in mind, allowing it to be reconfigured or expanded to meet the evolving needs of its drug pipeline. "This investment reflects our confidence in America’s continued leadership in biopharmaceutical innovation," said Chief Executive Christopher Boerner in a statement.

Industry Context

This announcement aligns with a broader trend among major pharmaceutical companies, including Pfizer, Eli Lilly, and Johnson & Johnson, to increase their manufacturing footprint within the United States. The move by Bristol Myers is a significant step in onshoring the production of critical medicines, a focus for the industry following pressure from the Trump administration to bolster domestic supply chains.

Read next

More on Stocks
Back to latest news

LATEST